Ken Griffin Lantern Pharma Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 17,100 shares of LTRN stock, worth $54,378. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,100
Previous 4,600
271.74%
Holding current value
$54,378
Previous $14,000
328.57%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding LTRN
# of Institutions
35Shares Held
2.41MCall Options Held
17.1KPut Options Held
1.3K-
Bios Capital Management, LP Fort Worth, TX1.21MShares$3.84 Million5.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA364KShares$1.16 Million0.0% of portfolio
-
Cm Management, LLC200KShares$636,0000.77% of portfolio
-
Geode Capital Management, LLC Boston, MA90.5KShares$287,8020.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny88.8KShares$282,3840.0% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $34.4M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...